Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Abstract: An object of the present invention is to provide a solid pharmaceutical composition which suppresses the characteristic bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has a good storage stability of the-aforementioned compound or a salt thereof. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a carboxylic acid whose solubility in water at 25° C. is 50 g/100 g H2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.

Abstract: An object of the present invention is to provide a pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof at a high concentration, with a characteristic bitter taste masked, and a manufacturing method thereof. The present invention provides a pharmaceutical composition comprising fine granules having a core comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof, and a binder; and a polymer layer with which a surface of the core is coated, wherein the fine granules have a roundness of 0.8 or more and a content of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof in the fine granules is 30 to 90% by mass.

Abstract: The object of the present invention is to provide a solid pharmaceutical composition in which both the pre-bitter taste and the post-bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof are suppressed. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a compound having at least one hydrocarbon group having 8 to 18 carbon atoms and a sulfo group or a salt thereof.

Abstract: An object of the present invention is to provide a solid pharmaceutical composition which suppresses the characteristic bitter taste of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and has a good storage stability of the-aforementioned compound or a salt thereof. The present invention provides a solid pharmaceutical composition comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and a carboxylic acid whose solubility in water at 25° C. is 50 g/100 g H2O or less, wherein pH of a solution obtained when the solid pharmaceutical composition is dissolved or suspended in a 10 mmol/L KCl solution such that 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or the salt thereof is 1 mg/mL or 8.96 mg/mL is 4.8 or less.

Abstract: An orally disintegrating tablet including: fine granules, each fine granule having, at its center, an active pharmaceutical ingredient-containing core that includes butylscopolamine bromide and water-insoluble particles, and having an intermediate layer that includes water-insoluble particles and coats the active pharmaceutical ingredient-containing core, and a bitterness-masking layer that includes talc and at least one water-insoluble polymer, in sequence from the active pharmaceutical ingredient-containing core side; and an excipient component positioned on the outside of the fine granules, and a method for producing the same.

Abstract: Provided are a propofol-containing oil-in-water emulsion composition having high stability even in a case in which the emulsion composition is charged into a plastic container; and a method for producing the same. Provided is a propofol-containing oil-in-water emulsion composition including at least one selected from the group consisting of trishydroxymethylaminomethane, phosphoric acid, and triethanolamine; propofol; an oily component; an emulsifier; and water, in which a dissolved oxygen concentration is 5 mg/L or less and an average emulsion particle size is 180 nm or less.

Abstract: A wireless LAN board includes a wired LAN connector connected to a wired LAN board, an antenna connecting terminal connected with an antenna for performing radio signal transmission/reception, a wired LAN section connected to the wired LAN connector to transmit/receive a data signal to/from the wired LAN board, a wireless LAN section connected to the antenna connecting terminal to transmit/receive a data signal to/from an external device with the use of a radio signal through the antenna, and a controller section connected to the wired LAN section and the wireless LAN section to control the wired LAN section and the wireless LAN section.